| TheraSphere (yttrium 90 microspheres) / Boston Scientific |
2009-016475-29: Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) |
|
|
| Ongoing | 3 | 50 | Europe | Suspension for injection, TheraSphere | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | advanced hepatocellular carcinoma (HCC) with portal vein thrombosis | | | | |
| Active, not recruiting | 3 | 92 | RoW | TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE) | Boston Scientific Corporation | Inoperable Hepatocellular Carcinoma | 12/25 | 10/26 | | |
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer |
|
|
| Not yet recruiting | 2 | 84 | Europe | Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere | Clinics of Munich University LMU, Astra Zeneca, Boston Scientific | Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04] | | | | |
2021-001575-16: Selective Internal Radiation Therapy and Capecitabine (chemotherapy) treatment for liver cancer Traitement par Radiothérapie Interne Sélective et Capecitabine (chimiothérapie) dans le cancer du foie |
|
|
| Not yet recruiting | 2 | 62 | Europe | CAPECITABINE ACCORD, THERASPHERE, Coated tablet, Radiopharmaceutical precursor, solution, CAPECITABINE ACCORD, THERASPHERE | Centre Régional de lutte contre le Cancer Eugène Marquis, Boston Scientific Corporation, Centre Régional de lutte contre le cancer Eugène Marquis | Patients having operable intrahepatic cholangiocarcinoma Patients présentant un cholangiocarcinome intra-hépatique résécable, Biliary tract cancer Cancer des voies biliaires, Diseases [C] - Cancer [C04] | | | | |
2021-001907-33: A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere alone versus receiving radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment) Estudio clínico para evaluar la seguridad y la eficacia de los sujetos con carcinoma hepatocelular (CHC) que reciben radioterapia con TheraSphere sola frente a los que reciben radioterapia con TheraSphere seguida de inmunoterapia (tratamiento con durvalumab y tremelimumab). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Durvalumab, Tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion | Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation, Boston Scientific Corporation | hepatocellular carcinoma carcinoma hepatocelular, a cancer that starts in the liver un cáncer que comienza en el hígado, Diseases [C] - Cancer [C04] | | | | |
RESOLVE, NCT06166576: Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis |
|
|
| Recruiting | 2 | 30 | RoW | Ablative radioembolization | Seoul National University Hospital | Hepatocellular Carcinoma | 11/27 | 11/27 | | |
NCT05620771: Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk |
|
|
| Recruiting | 2 | 84 | US | Atezolizumab and Bevacizumab, Y90 + TKI | Northwestern University, National Cancer Institute (NCI) | Hepatocellular Carcinoma | 07/24 | 07/25 | | |
ArTisaN, NCT04362436: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets |
|
|
| Recruiting | 2 | 24 | Europe | TheraSpheres Selective Internal Radiation Therapy (SIRT) | Imperial College London, Biocompatibles UK Ltd, a BT International group company | Neuroendocrine Tumors, Liver Metastases | 09/24 | 09/24 | | |
SIRTCI, NCT04659382: Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 52 | Europe | Atezolizumab, Therasphere, XELOX, Bevacizumab | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy | 10/24 | 10/24 | | |
NCT06627244: Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma |
|
|
| Not yet recruiting | 2 | 30 | US | Tebentafusp, Tebentafusp-tebn, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization, Y-90 TARE | University of Miami, Immunocore Ltd | Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver | 12/27 | 12/30 | | |
EMERALD-Y90, NCT06040099: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE |
|
|
| Recruiting | 2 | 100 | US | Durvalumab, MEDI4736, IMFINZI, Bevacizumab, AVASTIN, ZIRABEV, Transarterial Radioembolization (TARE), TheraSphere | AstraZeneca | Hepatocellular Carcinoma (HCC) | 10/26 | 10/26 | | |
| Recruiting | 2 | 100 | Europe, US | TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 06/27 | 06/27 | | |
SOLID, NCT04124991: Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC |
|
|
| Completed | 1/2 | 24 | RoW | Durvalumab, Imfinzi®, Radioembolization, TheraSphere™ | Seoul National University Hospital | Hepatocellular Carcinoma | 07/22 | 07/22 | | |
RENEGADE, NCT06432036: Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The Trial |
|
|
| Not yet recruiting | 1/2 | 25 | US | Angiogram, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Radioembolization, intra-arterial brachytherapy, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Survey Administration, Yttrium Y 90 Glass Microspheres, TheraSphere, Y-90 Therasphere | Jonsson Comprehensive Cancer Center, Boston Scientific Corporation | Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | 06/26 | 06/27 | | |
NCT03812562: Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection |
|
|
| Terminated | 1 | 2 | US | Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Yttrium Y 90 Glass Microspheres, TheraSphere | Northwestern University, Bristol-Myers Squibb, National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM |
|
|
| Recruiting | 1 | 12 | US | TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM) | Boston Scientific Corporation | Glioblastoma Multiforme, Recurrent Glioblastoma | 12/24 | 06/25 | | |
NCT04518748: Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy. |
|
|
| Recruiting | 1 | 65 | US | Yttrium-90, Y-90, Selective Internal Radiation Therapy, SIRT, Stereotactic Body Radiation Therapy, SBRT, PET/CT, Therasphere | University of Michigan Rogel Cancer Center, Department of Health and Human Services, National Institute for Biomedical Imaging and Bioengineering (NIBIB) | Liver Malignancy | 05/28 | 11/28 | | |
NCT00589030: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
|
|
| No Longer Available | N/A | | US | brachytherapy, yttrium Y 90 glass microspheres | City of Hope Medical Center | Liver Cancer | 09/14 | 09/14 | | |
NCT00701168: Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer |
|
|
| No Longer Available | N/A | | US | yttrium Y 90 microspheres (Therasphere®) | Leo W. Jenkins Cancer Center | Carcinoma, Hepatocellular, Neoplasm Metastasis | | | | |
NCT03686709: Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment |
|
|
| Recruiting | N/A | 20 | US | Post therapy PET/CT Imaging | University of Tennessee, Biocompatibles UK Ltd | Hepatocellular Carcinoma, Radiation Exposure | 06/19 | 12/19 | | |
NCT04517643: TheraSphere® For Treatment of Metastases in Liver |
|
|
| Completed | N/A | 4 | US | Therasphere Therapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Colorectal Cancer Metastatic, Colorectal Cancer | 09/21 | 12/22 | | |
NCT02960620: Therasphere for Unresectable Primary or Secondary Liver Neoplasia |
|
|
| No Longer Available | N/A | | US | TheraSphere Treatment | H. Lee Moffitt Cancer Center and Research Institute, Biocompatibles UK Ltd, BTG International Inc. | Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma | | | | |
NCT05233098: TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. |
|
|
| Completed | N/A | 5 | US | Technetium-99m macroaggregated albumin (Tc-99m MAA) | Boston Scientific Corporation | Hepatocellular Carcinoma | 06/23 | 06/23 | | |
PROACTIF, NCT04069468: Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | N/A | 500 | Europe | TheraSphere, Yttrium-90 Glass Microspheres | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 01/24 | 01/25 | | |
| Completed | N/A | 202 | RoW | Therasphere | Ankara University, Boston Scientific Corporation | Transarterial Radioembolization | 03/24 | 04/24 | | |
VOYAGER, NCT06192758: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device |
|
|
| Suspended | N/A | 36 | US | TheraSphere PCa, TheraSphere PCa - Yttrium-90 Glass Microspheres | Boston Scientific Corporation | Prostate, Cancer | 11/27 | 08/32 | | |
NCT03896646: Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) |
|
|
| Active, not recruiting | N/A | 42 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Hepatobiliary Iminodiacetic Acid Scan, HIDA Scan, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Yttrium Y 90 Glass Microspheres, TheraSphere, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma | 09/24 | 09/24 | | |
NCT03059030: Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia |
|
|
| Terminated | N/A | 7 | US | TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc. | Northwestern University, BTG International Inc. | Thrombocytopenia, Cirrhosis | 04/24 | 04/24 | | |
REALM, NCT05953961: 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia |
|
|
| Recruiting | N/A | 50 | US | Therasphere 90Y, Microwave Ablation | Ochsner Health System, Boston Scientific Corporation | Carcinoma, Hepatocellular | 08/26 | 01/27 | | |
| DC Bead (E7040) / Eisai, Boston Scientific |
2013-001244-56: An open, multicenter, single dose, parallel study, evaluating the releaseand disposition of doxorubicin and its active metabolite (doxorubicinol)after an intra-arterial injection into the liver of an emulsion containingdoxorubicin or doxorubicin loaded into microparticulate beads in patientswith intermediate stage primary liver cancer. |
|
|
| Ongoing | 4 | 28 | Europe | DC Bead, iodine, doxorubicin hcl, DEB, DOX, DC Bead, Lipodol ultra fluide, Doxorubicin Teva, doxorubicin hydrochloride for injection (Adriamycine), DC Bead, Lipodol ultra fluide, Doxorubicin Teva, doxorubicin hydrochloride for injection (Adriamycine) | Department of Pharmacy, Uppsala University, Deparment of Pharmacy, Uppsala University | Intermediate hepatocellular carcinoma | | | | |
NCT01004978: Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
|
|
| Completed | 3 | 235 | US | Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Pharmacological Study, Placebo Administration, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib | National Cancer Institute (NCI) | Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | 02/21 | 12/22 | | |
| Ongoing | 2 | 10 | Europe | Concentrate for solution for infusion | | Patients with breast carcinoma and liver-dominant metastasis, Patients with breast carcinoma and liver-dominant metastasis, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900023798: Safety and effeficacy of drug-eluting beads chemoembolization for hepatocelluar carcinoma: comparison of DC Bead M1 versus Lipidol |
|
|
| Recruiting | N/A | 100 | | DC Bead M1 ;Lipidol | Intervention Department of the Second Xiangya Hospital of Central South University; The Second Xiangya Hospital of Central South University, Self-finance | hepatocellular cacinoma | | | | |
| Varithena (polidocanol injectable foam) / Boston Scientific |
| Terminated | 4 | 43 | US | Varithena®, FDA-approved Endothermal Ablation (ETA) systems | Boston Scientific Corporation | Varicose Veins | 04/24 | 04/24 | | |
NCT05633277: Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections |
|
|
| Recruiting | N/A | 30 | US | Polidocanol, Radio Frequency Ablation, Endovenous Laser Ablation Therapy, Varithena, Venaseal, Sotradecol | ProMedica Health System, Jobst Vascular Institute | Venous Reflux, Venous Insufficiency, Venous Ulcer, Venous Disease | 09/23 | 03/24 | | |
| Proxcelan Cesium-131 (cesium-131) / Perspective Therap |
NCT04690348: Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study |
|
|
| Recruiting | 2 | 99 | US | Craniotomy, Cesium-131 brachytherapy | Memorial Sloan Kettering Cancer Center, GT Medical Technologies, Inc. | Recurrent Brain Metastases | 12/25 | 12/25 | | |
NCT02467738: Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer |
|
|
| Completed | 1 | 30 | US | Brachytherapy, Cesium-131, Conventional surgery | Sidney Kimmel Cancer Center at Thomas Jefferson University | Recurrent Head and Neck Carcinoma | 08/18 | 05/20 | | |
| BTG-002814 / Boston Scientific |
2017-002517-64: A trial of tiny beads linked to an anti-cancer drug (vandetanib) injected into liver tumours |
|
|
| Not yet recruiting | 1/2 | 56 | Europe | Vandetanib Eluting Radiopaque Bead, BTG-002814, Implant | Biocompatibles UK Ltd, Biocompatibles UK Ltd | Hepatocellular Carcinoma (HCC), Liver Cancer, Diseases [C] - Cancer [C04] | | | | |
| BGC-201531 / Ariel |
| No trials found |
| SRT-149 / Boston Scientific |
| No trials found |
| CiVax (CoVaccine HT adjuvant based COVID-19 vaccine) / Soligenix, Boston Scientific, University of Hawaii Cancer Center |
| No trials found |
